A laboratory and the University of Antioquia in Colombia test the effectiveness of cannabis extract to kill the Covid-19 virus.
The pharmaceutical company Pideka SAS in collaboration with the University of Antioquia in Colombia carry out tests on the effectiveness of cannabis extract in protecting cells against sars-cov-2.
Martha Liliana Vega, technical director of manufacturing at said company, explained that the latest results revealed that the cannabis substance protected a healthy cell by 62% from the virus that causes Covid-19.
In an interview for Forbes México, he explained that Pideka SAS is a company that has a license to cultivate and transform the marijuana plant in various derivations; as well as to investigate its effectiveness as an anti-inflammatory and treatment for viruses, fungi and bacteria.
He added that before the start of the coronavirus pandemic in the world, the company to which it belongs made an agreement with the immunovirology group of the University of Antioquia to study the effectiveness of cannabis extracts against sars-cov-2 .
Also read: Russia announces its third vaccine and authorizes clinical trials
The pharmaceutical chemist reported that in the initial cytotoxicity studies the researchers ruled out damage to healthy cells with substances diluted in one, 10 and 100 milliliters of the marijuana extract.
After that, he explained that the cell culture was placed with said solution under specific conditions for its absorption and to test its effectiveness in protecting the coronavirus, which had a 62% positive result.
He pointed out that his studies were compared with chloroquine, a drug that has had a 73% response against the virus that causes this disease.
Vega clarified that several tests are still missing, such as preclinical and clinical studies in their different phases so that a medical product can be arranged; However, he reiterated that they hope to increase said effectiveness against covid-19 to 80 or 90%.
It may interest you: There is still no commercial agreement with Russia for vaccine: López-Gatell
He said that they have in mind that with this they can develop a wide variety of items, from an anti-inflammatory drug, a preventive antiviral, to a disinfectant for hospital, industrial or home surfaces.
He indicated that in Mexico they are collaborating with the institute of Dr. Alberto Checa, where they will continue with in vitro studies on anti-inflammatory activity, although later they will continue with the process in Colombia.
He stressed that it is too early to say a date for when human studies could begin, as it would be speculative.
He added that the company's directors are in dialogue with the Colombian government to request support for the agility of the studies, they are also in contact with the National Institute of Health and research groups from other universities.
He announced that they are in talks with other entities in Spain, but at the moment he cannot reveal more information.